Varian Medical releases new Velocity cancer imaging software

Varian Medical (NYSE:VAR) said today it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module. The newly launched Velocity 4.0’s Rapidsphere module is designed for Y90 selective internal radiation therapy dosimetry analysis and provides improved information on tumor responses and normal-tissue toxicity for patients undergoing SIRT, the Palo Alto, Calif.-based company said. The Velocity 4.0 software includes the company’s Velocity M3i multi-modality motion imaging component, the Velocity Aria sync component and the Velocity tumor &dose tracking component. “At Varian, we are focused on providing clinicians with powerful and comprehensive solutions that enable them to provide personalized cancer therapy for patients. Patient-specific 3D imaging and dosimetry for targeted cancer therapy delivery is important for predicting the tumor’s response to therapy. The Rapidsphere module is a significant advancement for interventional radiologists performing Y90 SIRT,” Varian oncology systems biz prez Kolleen Kennedy said in a press release. Last week, Brainlab said it inked a deal with Varian looking to support interoperability between Brainlab’s ExacTrac and Varian’s Clinac platform, TrueBeam and Edge systems. The post Varian Medical releases new Velocity cancer imaging software appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Imaging Oncology Software / IT Varian Medical Systems Source Type: news

Related Links:

Conclusion: In spite of the rapid development of external beam radiation therapy brachytherapy continues to remain an important mode of therapy and is often a default treatment when external beam radiation option is limited.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
This study aims to report radiotherapy utilization and fractionation patterns during the first course of cancer treatment.MethodsWe extracted all solid tumor cases from 2004 to 2014 in the National Cancer Data Base, which captures only the first course of treatment. Patients were subcategorized by disease site: breast, central nervous system (CNS), gastrointestinal, genitourinary, gynecologic, head and neck (HN), musculoskeletal, skin, or thoracic. Receipt of therapy was identified (systemic, surgical, or radiation therapy). Radiotherapy was subcategorized as external beam radiation therapy (EBRT) (conventional and stereot...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
In conclusion, this study shows that stable radioactive HoPO4-MS can be prepared with suitable properties to be used for cancer therapy.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
This study aims to report radiotherapy utilization and fractionation patterns during the first course of cancer treatment.MethodsWe extracted all solid tumor cases from 2004 to 2014 in the National Cancer Data Base, which captures only the first course of treatment. Patients were subcategorized by disease site: breast, central nervous system (CNS), gastrointestinal, genitourinary, gynecologic, head and neck (HN), musculoskeletal, skin, or thoracic. Receipt of therapy was identified (systemic, surgical, or radiation therapy). Radiotherapy was subcategorized as external beam radiation therapy (EBRT) (conventional and stereot...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
In conclusion, this study shows that stable radioactive HoPO4-MS can be prepared with suitable properties to be used for cancer therapy. Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusion We found a steady decrease in the percent of patients receiving radiotherapy in their first course of treatment, and a global decline in the mean number of fractions delivered per patient receiving EBRT, compared with an increase in systemic therapy and stable surgery utilization. These results illustrate the changing use of radiotherapy and fractionation during first-line therapy in contemporary US cancer care.
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
For men diagnosed with aggressive cancer that’s confined to the prostate and nearby tissues, the overarching goal of treatment is to keep the disease from spreading (or metastasizing) in the body. Doctors can treat these men with localized therapies, such as surgery and different types of radiation that target the prostate directly. And they can also give systemic treatments that kill off rogue cancer cells in the bloodstream. Hormonal therapy, for instance, is a systemic treatment that kills prostate cancer cells by depriving them of testosterone, which fuels their growth. Now a new study shows that a mix of differe...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Men's Health Prostate Health Source Type: blogs
Varian Medical Systems has revealed plans to acquire interventional oncology specialist Sirtex Medical for $1.3 billion. The proposed acquisition comes about a year after the New South Wales, Australia-based company fired CEO Gilman Wong, following an investigation into his share trading. In January 2017, the Sydney Morning Herald reported Wong was terminated after an investigation revealed he received $2.1 million from the sale of shares in Sirtex about one day after he told investors at the company’s annual general meeting that the company expected “double-digit” dose sales in 2017. Wong was replaced ...
Source: MDDI - Category: Medical Devices Authors: Tags: Medical Device Business Source Type: news
Conclusion: Over recent years, radiotherapy techniques have been greatly developed which create various suitable conditions for the treatment of different cancers while sparing normal tissues. As the radiotherapy techniques developed, tumor covering and precision on dose delivery increased.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Authors: Suh DH, Kim M, Kim K, Kim HJ, Lee KH, Kim JW Abstract In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-f...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Cancer Therapy | Radiation Therapy | Radiology | Toxicology